BRAIN Biotech AG

XETRA BNN.DE

BRAIN Biotech AG Operating Cash Flow for the year ending September 30, 2023: USD -4.46 M

BRAIN Biotech AG Operating Cash Flow is USD -4.46 M for the year ending September 30, 2023, a -206.46% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • BRAIN Biotech AG Operating Cash Flow for the year ending September 30, 2022 was USD -1.46 M, a 67.81% change year over year.
  • BRAIN Biotech AG Operating Cash Flow for the year ending September 30, 2021 was USD -4.52 M, a 19.07% change year over year.
  • BRAIN Biotech AG Operating Cash Flow for the year ending September 30, 2020 was USD -5.59 M, a -51.67% change year over year.
  • BRAIN Biotech AG Operating Cash Flow for the year ending September 30, 2019 was USD -3.68 M, a 41.41% change year over year.
Key data
Date Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid
Market news
Loading...
XETRA: BNN.DE

BRAIN Biotech AG

CEO Mr. Adriaan Moelker
IPO Date Feb. 9, 2016
Location Germany
Headquarters Darmstädter Strasse 34-36
Employees 319
Sector Health Care
Industries
Description

BRAIN Biotech AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical industries in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates in two segments, BioScience and BioIndustrial. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and nature-based active ingredients for product development in the food, animal feed, skin care, cosmetics, and chemical industries. The company also identifies and develops optimized enzymes and biocatalysts for the production of food and beverages, and wound care preparations or lubricants, as well as for starch processing of bioethanol production; and microorganisms as the functional biomass for optimized industrial production processes, recycling of greenhouse gas CO2 as an industrial raw material, and extraction of precious and rare earth metals. It has strategic partnerships with AnalytiCon Discovery GmbH and Roquette to develop natural sweeteners and sweet taste enhancers. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. BRAIN Biotech AG was founded in 1993 and is headquartered in Zwingenberg, Germany.

Similar companies

FYB.DE

Formycon AG

USD 60.50

-1.24%

COP.DE

CompuGroup Medical SE & Co. KGaA

USD 22.41

0.70%

MDG1.DE

Medigene AG

USD 1.09

3.54%

StockViz Staff

January 15, 2025

Any question? Send us an email